Thomas J. Lewis
Health Revival Partners, USA
Title: Life, blood and eye tests to complement stem cell therapy
Biography
Biography: Thomas J. Lewis
Abstract
Critical to broad acceptance of newer technologies is an understanding of the causes behind both success and failure of treatments. As humans age, their immune system undergoes immunosenescence. The progressive deterioration of the immune system is one contributing factor to the characteristic decline in stem cell activity that also accompanies aging, at least with regard to certain types of stem cells. Underlying low-grade chronic disease and accompanying immune activation and inflammation also drive senescence processes and concomitantly impacts stem cell efficacy. It’s well established that inflammatory sites and an inflammatory milieu are hostile towards the survival of transplanted cells. Practitioners who apply stem cell therapy have a significant opportunity to take a leading role in understanding and reversing accelerated aging. Stem cell therapy, to be most impactful, should be delivered along with anti-inflammatory strategies. Key to this approach is understanding the immune system/inflammatory status of each patient. Presented here is a novel Harvard Medical School and MIT developed a systems approach to accurately and precisely measure immune and chronic inflammatory status. The Chronic Disease Assessment™ and Chronic Disease Temperature™ provide a subjective and objective easure of immune status and include a path to reducing inflammation. The eye plays an important role in this program. Cataract, for example, is a sign of systemic inflammation, stem cells disease, high cardiovascular risk, and early mortality. The lens of the eye uniquely acts like a single large stem cell. The connection between life risks, biomarkers and eye pathologies will be discussed in the context of a holistic approach to successful stem cell therapy.